Signal
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis trials, revealing that deaths from infections, diabetes complications and ...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-21 23:28 UTCUpdated 2026-04-22 11:30 UTC
rss
ms_fierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
New data build case for Roche's oral BTK drug for MS Phil.Taylor Wed, 22/04/2026 - 11:30.
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
New data build case for Roche's oral BTK drug for MS
pharmaphorum · pharmaphorum.com · 2026-04-22 11:30 UTC
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis trials, revealing that deaths from infections, diabetes complications and an accident contribu...
Fierce Biotech · fiercebiotech.com · 2026-04-21 23:28 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- pharmaphorum.com (1)
- fiercebiotech.com (1)